![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://plexusdx.com/cdn/shop/articles/b2_d638f993-3a86-4502-9ad9-c69175f3d4e7.jpg?v=1778863584&width=4608)
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://www.frontiersin.org/files/Articles/440649/xml-images/fendo-10-00080-g0003.webp)
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://s7d6.scene7.com/is/image/questdiagnostics/z-codes-Picture7?wid=866&hei=668&dpr=off)
Quick Dispatch:
Your glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity ships.
Need Help?
Questions about glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity in your area.
Carmot Therapeutics
23.21
Roche Announces Positive Topline Results from Phase II Study for Dual GLP-1/GIP Receptor Agonist : r/mounjarouk
29.72
The challenge of developing oral alternatives to Ozempic, Wegovy and Mounjaro
26.60
Crystal structure of the GLP-1 receptor bound to a peptide agonist
28.27
Roche's New GLP-1 Hits 22% Weight Loss! Can it beat Zepbound?
27.67
Everyone's buying. Roche isn't. While Big Pharma drops billions chasing GLP- 1 hype and patching patent cliffs, Roche is playing a different game—no bidding wars, no overpaying, just building. $50B into U.S. infrastructure
25.18
Roche's Genentech vows to expand NC anti-obesity drug plant
29.15
